Cantor Fitzgerald raised the firm’s price target on Gilead (GILD) to $80 from $70 and keeps a Neutral rating on the shares post the Q3 report. The firm cites higher product sales continued outperformance from HIV and Veklury for the target increase.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD: